Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.

Clinical characteristic Diffuse midline glioma H3 K27-altered Midline location Molecular feature Prognostic factor Survival

Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
27 Jul 2024
Historique:
received: 09 03 2024
accepted: 27 05 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 26 7 2024
Statut: epublish

Résumé

This study aims to elucidate the clinical and molecular characteristics, treatment outcomes and prognostic factors of patients with histone H3 K27-mutant diffuse midline glioma. We retrospectively analyzed 93 patients with diffuse midline glioma (47 thalamus, 24 brainstem, 12 spinal cord and 10 other midline locations) treated at 24 affiliated hospitals in the Kansai Molecular Diagnosis Network for CNS Tumors. Considering the term "midline" areas, which had been confused in previous reports, we classified four midline locations based on previous reports and anatomical findings. Clinical and molecular characteristics of the study cohort included: age 4-78 years, female sex (41%), lower-grade histology (56%), preoperative Karnofsky performance status (KPS) scores ≥ 80 (49%), resection (36%), adjuvant radiation plus chemotherapy (83%), temozolomide therapy (76%), bevacizumab therapy (42%), HIST1H3B p.K27M mutation (2%), TERT promoter mutation (3%), MGMT promoter methylation (9%), BRAF p.V600E mutation (1%), FGFR1 mutation (14%) and EGFR mutation (3%). Median progression-free and overall survival time was 9.9 ± 1.0 (7.9-11.9, 95% CI) and 16.6 ± 1.4 (13.9-19.3, 95% CI) months, respectively. Female sex, preoperative KPS score ≥ 80, adjuvant radiation + temozolomide and radiation ≥ 50 Gy were associated with favorable prognosis. Female sex and preoperative KPS score ≥ 80 were identified as independent good prognostic factors. This study demonstrated the current state of clinical practice for patients with diffuse midline glioma and molecular analyses of diffuse midline glioma in real-world settings. Further investigation in a larger population would contribute to better understanding of the pathology of diffuse midline glioma.

Identifiants

DOI: 10.1186/s40478-024-01808-w PMID: 39061104
pubmed: 39061104
doi: 10.1186/s40478-024-01808-w
pii: 10.1186/s40478-024-01808-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120

Subventions

Organisme : JSPS KAKENHI
ID : No. 23K08529

Informations de copyright

© 2024. The Author(s).

Références

Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S et al (2017) Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 38:795–800. https://doi.org/10.3174/ajnr.A5076
doi: 10.3174/ajnr.A5076 pubmed: 28183840 pmcid: 5394943
Aboian MS, Tong E, Solomon DA, Kline C, Gautam A, Vardapetyan A et al (2019) Diffusion characteristics of pediatric diffuse midline gliomas with histone H3–K27M mutation using apparent diffusion coefficient histogram analysis. AJNR Am J Neuroradiol 40:1804–1810. https://doi.org/10.3174/ajnr.A6302
doi: 10.3174/ajnr.A6302 pubmed: 31694820 pmcid: 6907069
Alvi AM, Ida CM, Paolini MA, Kerezoudis P, Meyer J, Fritcher EGB et al (2019) Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation. Mod Pathol 32(9):1236–1243. https://doi.org/10.1038/s41379-019-0271-3
doi: 10.1038/s41379-019-0271-3 pubmed: 31028365
Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M et al (2016) TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun 8:201. https://doi.org/10.1186/s40478-020-01078-2
doi: 10.1186/s40478-020-01078-2
Auffret L, Ajlil Y, Tauziede-Espariat A, Kergrohen T, Puiseux C, Riffaud L et al (2024) A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinoco-radiological and histomolecular characterization. Acta Neuropathol 147:2. https://doi.org/10.1007/s00401-023-02651-4
doi: 10.1007/s00401-023-02651-4
Bin-Alamer O, Jimenez AE, Azad TD, Bettegowda C, Mukherjee D et al (2022) H3K27M-altered diffuse midline gliomas among adult patients: A systematic review of clinical features and survival analysis. World Neurosurg 165:e251-264. https://doi.org/10.1016/j.wneu.2022.06.020
doi: 10.1016/j.wneu.2022.06.020. pubmed: 35697228
Bozkurt SU, Dagcinar A, Tanrikulu B, Comunoglu N, Meydan BC, Ozek M et al (2018) Significance of H3K27M mutation with specific histomorphological features and associated molecular alternations in pediatric high-grade glial tumors. Childs Nerv Syst 34:107–116. https://doi.org/10.1007/s00381-017-3633-5
doi: 10.1007/s00381-017-3633-5 pubmed: 29063957
Carrano A, Juarez JJ, Incontri D, Ibarra A, Cazares HG (2021) Sex-specific differences in glioblastoma. Cells 10:1783. https://doi.org/10.3390/cells10071783
doi: 10.3390/cells10071783 pubmed: 34359952 pmcid: 8303471
Castel D, Philippe C, Calmon R, Dret LL, Truffaux N, Boddaert N et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815–827. https://doi.org/10.1007/s00401-015-1478-0
doi: 10.1007/s00401-015-1478-0 pubmed: 26399631 pmcid: 4654747
Chai RC, Zhang YW, Liu YQ, Chang YZ, Pang B, Jiang T et al (2020) The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol Commun 8:40. https://doi.org/10.1186/s40478-020-00913-w
doi: 10.1186/s40478-020-00913-w pubmed: 32228694 pmcid: 7106747
Chia N, Wong A, Teo K, Tan AP, Vellayappan BA, Yeo TT et al (2021) H3K27M-mutant, hemispheric diffuse glioma in an adult patient with prolonged survival. Neuro Oncol Adv 3(1):1–5. https://doi.org/10.1093/noajnl/vdab135
doi: 10.1093/noajnl/vdab135
Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E et al (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic gliomas: a report from the children’s oncology group. Neuro Oncol 13(4):410–416. https://doi.org/10.1093/neuonc/noq205
doi: 10.1093/neuonc/noq205 pubmed: 21345842 pmcid: 3064697
Dono A, Takayasu T, Ballester LY, Esquenazi Y (2020) Adult diffuse midline gliomas: clinical, radiological, and genetic characteristics. J Clin Neurosci 82:1–8. https://doi.org/10.1016/j.jocn.2020.10.005
doi: 10.1016/j.jocn.2020.10.005 pubmed: 33317715 pmcid: 7748263
Ebrahimi A, Skardelly M, Schuhmann MU, Ebinger M, Reuss D, Neumann M et al (2019) High frequency of H3 K27M mutations in adult midline gliomas. J Cancer Res Clin Oncol 145:839–850. https://doi.org/10.1007/s00432-018-02836-5
doi: 10.1007/s00432-018-02836-5 pubmed: 30610375
Enomoto T, Aoki M, Hamasaki M, Abe H, Nonaka M, Inoue T et al (2020) Midline glioma in adults: clinicopathological, genetic, and epigenetic analysis. Neurol Med Chir (Tokyo) 60:136–146. https://doi.org/10.2176/nmc.oa.2019-0168
doi: 10.2176/nmc.oa.2019-0168 pubmed: 31902873
Feng J, Hao S, Pan C, Wang Y, Wu Z, Zhang J et al (2015) The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Human Pathol 46:1626–1632. https://doi.org/10.1016/j.humpath.2015.07.002
doi: 10.1016/j.humpath.2015.07.002
Funata N, Nobusawa S, Nakata S, Yamazaki T, Takabagake K, Koike T et al (2018) A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor. Brain Tumor Pathol 35:29–35. https://doi.org/10.1007/s10014-017-0305-9
doi: 10.1007/s10014-017-0305-9 pubmed: 29264735
Gilbert AR, Zaky W, Gokden M, Fuller CE, Ocal E, Leeds NE et al (2018) Extending the neuroanatomic territory of diffuse midline glioma, K27M mutant: pineal region origin. Pediatr Neourosurg 53:59–63. https://doi.org/10.1159/000481513
doi: 10.1159/000481513
Gutierrez DR, Jones C, Varlet P, Mackay A, Warren D, Warmuth-Metz M et al (2020) Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in HERBY Phase II Trial. Clin Cancer Res 26(8):1856–1865. https://doi.org/10.1158/1078-0432.CCR-19-3154
doi: 10.1158/1078-0432.CCR-19-3154
Hassan U, Latif M, Yousaf I, Anees SB, Mushtaq S, Akhtar N et al (2021) Morphological spectrum and survival analysis of diffuse midline glioma with H3K27M mutation. Cureus 13(8):e17267. https://doi.org/10.7759/cureus.17267
doi: 10.7759/cureus.17267 pubmed: 34540489 pmcid: 8448278
Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A et al (2018) Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Oncotarget 98:37112–37124. https://doi.org/10.18632/oncotarget.26430
doi: 10.18632/oncotarget.26430
Ishibashi K, Inoue T, Fukushima H, Watanabe Y, Iwai Y, Sakamoto H et al (2016) Pediatric thalamic glioma with H3F3A K27M mutation, which was detected before and after malignant transformation: a case report. Childs Nerv Syst 32:2433–2438. https://doi.org/10.1007/s00381-016-3161-8
doi: 10.1007/s00381-016-3161-8 pubmed: 27392443
Jang SW, Song SW, Kim YH, Cho YH, Hong SH, Kim JH et al (2022) Clinical features and prognosis of diffuse midline glioma: A series of 24 cases. Brain Tumor Res Treat 10(4):255–264. https://doi.org/10.14791/btrt.2022.0035
doi: 10.14791/btrt.2022.0035 pubmed: 36347640 pmcid: 9650120
Karlowee V, Amatya VJ, Takayasu T, Takano M, Yonezawa U, Takeshima Y et al (2019) Immunostaining of increased expression of enhancer of zeste homolog 2(EZH2) in diffuse midline glioma H3K27M-Mutant patients with poor survival. Pathobiology 86:152–161. https://doi.org/10.1159/000496691
doi: 10.1159/000496691 pubmed: 31096221
Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M et al (2018) Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol 20(1):123–131. https://doi.org/10.1093/neuonc/nox149
doi: 10.1093/neuonc/nox149 pubmed: 29016894
Kleinschmidt-DeMasters BK, Mulcahy Levy JM (2018) H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis. Clin Neuropathol 37:53–63. https://doi.org/10.5414/NP301085
doi: 10.5414/NP301085 pubmed: 29393845 pmcid: 5822176
Komori T (2021) The molecular framework of pediatric-type diffuse gliomas: shifting toward the revision of the WHO classification of tumors of the central nervous system. Brain Tumor Pathol 38:1–3. https://doi.org/10.1007/s10014-020-00392-w
doi: 10.1007/s10014-020-00392-w pubmed: 33398472
Liu Y, Hua W, Li Z, Wu B, Liu W (2019) Clinical and molecular characteristics of thalamic gliomas: retrospective report of 26 cases. World Neurosurg 126:e1169–e1182. https://doi.org/10.1016/j.wneu.2019.03.061
doi: 10.1016/j.wneu.2019.03.061 pubmed: 30885860
Lopez G, Bush NAO, Berger MS, Perry A, Solomon DA (2017) Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. Acta Neuropathol Commun 5:38. https://doi.org/10.1186/s40478-017-0440-x
doi: 10.1186/s40478-017-0440-x pubmed: 28506301 pmcid: 5433088
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106 pubmed: 34185076 pmcid: 8328013
Maeda S, Ohka F, Okuno Y, Aoki K, Motomura K, Takeuchi K et al (2020) H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant. Acta Neuropathol Commun 8:8. https://doi.org/10.1186/s40478-020-0882-4
doi: 10.1186/s40478-020-0882-4 pubmed: 32019606 pmcid: 7001313
Matsunaga K, Fukami S, Nakajima N, Ichimasu N, Kohno M (2023) Patient with diffuse midline glioma, H3 K27-altered, carrying an FGFR1 mutation who experienced thalamic hemorrhage: A case report and literature review. NMC Case Rep 10:309–314. https://doi.org/10.2176/jns-nmc.2023-0035
doi: 10.2176/jns-nmc.2023-0035
Meyronet D, Esteban-Mader M, Bonnet C, Joly MO, Uro-Coste E, Amiel-Benouaich A et al (2017) Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 19(8):1127–1134. https://doi.org/10.1093/neuonc/now274
doi: 10.1093/neuonc/now274 pubmed: 28201752 pmcid: 5570304
Ostrom QT, Kinnersley B, Wrensch MR, Eckel-Passow JE, Armstrong G, Rice T et al (2018) Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Sci Rep 8:1–15. https://doi.org/10.1038/s41598-018-24580-z
doi: 10.1038/s41598-018-24580-z
Park C, Kim TM, Bae JM, Yun H, Kim JW, Choi SH et al (2021) Clinical and genomic characteristics of adult diffuse midline glioma. Cancer Res Treat 53(2):389–398. https://doi.org/10.4143/crt.2020.694
doi: 10.4143/crt.2020.694 pubmed: 33171023
Peng Y, Ren Y, Huang B, Tang J, Jv Y, Mao Q et al (2023) A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma. Sci Rep 13:9970. https://doi.org/10.1038/s41598-023-37078-0
doi: 10.1038/s41598-023-37078-0 pubmed: 37340065 pmcid: 10282027
Picca A, Berzero G, Bielle F, Touat M, Savatovsky J, Polivka M et al (2018) FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology 90(23):e2086–e2094. https://doi.org/10.1212/WNL.0000000000005658
doi: 10.1212/WNL.0000000000005658 pubmed: 29728520
Pratt D, Natarajan SK, Banda A, Giannini C, Vats P, Koschmann C et al (2018) Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. Acta Neuropathol 135:299–301. https://doi.org/10.1007/s00401-018-1805-3
doi: 10.1007/s00401-018-1805-3 pubmed: 29302777 pmcid: 6018022
Qiu T, Chanchotisatien A, Qin Z, Wu J, Du Z, Zhang X et al (2020) Imaging characteristics of adult H3 K27M-mutant gliomas. J Neurosurg 133:1662–1670. https://doi.org/10.3171/2019.9.JNS191920
doi: 10.3171/2019.9.JNS191920
Rocca GL, Sabatino G, Altieri R, Signorelli F, Ricciardi L, Gessi M et al (2019) Significance of H3K27M mutation in “Nonmidline” high-grade gliomas of cerebral hemispheres. World Neurosurg 131:174–176. https://doi.org/10.1016/j.wneu.2019.08.024
doi: 10.1016/j.wneu.2019.08.024 pubmed: 31415896
Sasaki T, Fukai J, Kodama Y, Hirose T, Okita Y, Moriuchi S et al (2018) Characteristics and outcomes of elderly patients with diffuse gliomas: a multi-institutional cohort study by Kansai Molecular Diagnosis Network for CNS Tumors. J Neurooncol 140:329–339. https://doi.org/10.1007/s11060-018-2957-7
doi: 10.1007/s11060-018-2957-7 pubmed: 30076584 pmcid: 6244782
Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM et al (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 143:87–93. https://doi.org/10.1007/s11060-019-03134-x
doi: 10.1007/s11060-019-03134-x pubmed: 30864101 pmcid: 6482123
Schuller U, Iglauer P, Dorostkar MM, Mawrin C, Herms L et al (2021) Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. Acta Neuropathol 141:323–325. https://doi.org/10.1007/s00401-020-02259-y
doi: 10.1007/s00401-020-02259-y pubmed: 33433639 pmcid: 7847449
Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE et al (2020) Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neuro Oncol Adv 2(1):1–10. https://doi.org/10.1093/noajnl/vdaa142
doi: 10.1093/noajnl/vdaa142
Shah A, Jhawar S, Ai G, At G (2021) Corpus callosum and its connections: A fiber dissection study. World Neurosurg 151:e1024–e1035. https://doi.org/10.1016/j.wneu.2021.05.047
doi: 10.1016/j.wneu.2021.05.047 pubmed: 34033953
Shi S, Lu S, Jing X, Liao J, Li Q (2021) The prognostic impact of radiotherapy in conjunction with temozolomide in diffuse intrinsic pontine glioma. A systemic review and meta-analysis. World Neurosurg 148:e565-571. https://doi.org/10.1016/j.wneu.2021.01.024
doi: 10.1016/j.wneu.2021.01.024 pubmed: 33476781
Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJJ et al (2016) Diffuse midline gliomas with histone H3–K27M mutation: A series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26:569–580. https://doi.org/10.1111/bpa.12336
doi: 10.1111/bpa.12336 pubmed: 26517431
Stabellini N, Krebs H, Patil N, Waite K, Barnholtz-Sloan JS (2021) Sex difference in time to treat and outcomes for gliomas. Front Oncol 11:630597. https://doi.org/10.3389/fonc.2021.630597
doi: 10.3389/fonc.2021.630597 pubmed: 33680971 pmcid: 7933512
Swanson LW, Sporns O, Hahn JD (2016) Network architecture of the cerebral nuclei (basal ganglia) association and commissural connectome. Proc Natl Acad Sci 25:5972–5981. https://doi.org/10.1073/pnas.161318411
doi: 10.1073/pnas.161318411
Thomas A (2000) Functional anatomy of the basal ganglia. J Neurosci Nurs 32(5):250–253. https://doi.org/10.1002/mds.10138
doi: 10.1002/mds.10138
Thust S, Micallef C, Okuchi S, Brandner S, Kumar A, Mankad K et al (2021) Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults. Quant Imaging Med Surg 11(1):43–56. https://doi.org/10.21037/qims-19-954
doi: 10.21037/qims-19-954 pubmed: 33392010 pmcid: 7719951
Umehara T, Arita H, Yoshioka E, Shofuda T, Kanematsu D, Kinoshita M et al (2019) Distribution differences in prognostic copy number alteration profiles in IDH-wild type glioblastoma cause survival discrepancies across cohorts. Acta Neuropathol Commun 7:15. https://doi.org/10.1186/s40478-019-0749-8
doi: 10.1186/s40478-019-0749-8 pubmed: 31215469 pmcid: 6580599
Vuong HG, Ngo TNM, Le HT, Dunn IF (2022) The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas in influenced by patient age. J Neurooncol 158:405–412. https://doi.org/10.1007/s11060-022-04027-2
doi: 10.1007/s11060-022-04027-2 pubmed: 35606633
Vuong HG, Ngo TNM, Le HT, Jea A, Hrachova M, Battiste J et al (2022) Prognostic implication of patient age in H3K27M-mutant gliomas. Front Oncol 12:858148. https://doi.org/10.3389/fonc.2022.858148
doi: 10.3389/fonc.2022.858148 pubmed: 35371982 pmcid: 8971724
Wang L, Li Z, Zhang M, Piao Y, Chen L, Liang H et al (2018) H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Human Pathol 78:89–96. https://doi.org/10.1016/j.humpath.2018.04.015
doi: 10.1016/j.humpath.2018.04.015
Wang Y, Feng LL, Ji PG, Liu JH, Guo SC, Zhai YL et al (2021) Clinical feature and molecular markers on diffuse midline gliomas with H3K27M mutations: A 43 cases retrospective cohort study. Front Oncol 10:602553. https://doi.org/10.3389/fonc.2020.602553
doi: 10.3389/fonc.2020.602553 pubmed: 33659209 pmcid: 7917281
WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed. International Agency for Research on Cancer, Lyon; 2021.
Williams EA, Brastianos PK, Wakimoto H, Zolal A, Filbin MG, Cahill DP et al (2023) A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Acta Neuropathol 146:515–525. https://doi.org/10.1007/s00401-023-02609-6
doi: 10.1007/s00401-023-02609-6 pubmed: 37524847 pmcid: 10412483
Yabuno S, Kawauchi S, Umakoshi M, Uneda A, Fujii K, Ishida J et al (2021) Spinal cord diffuse midline glioma, H3K27M-mutant effectively treated with bevacizumab: A report of two cases. NMC Case Rep J 8:505–511. https://doi.org/10.2176/nmccrj.cr.2021-0033
doi: 10.2176/nmccrj.cr.2021-0033 pubmed: 35079510 pmcid: 8769434
Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki SO, Hata N, Akagi Y et al (2017) Prevalance and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol 34:103–112. https://doi.org/10.1007/s10014-017-0287-7
doi: 10.1007/s10014-017-0287-7 pubmed: 28447171
Zhao JP, Liu XJ, Lin HZ, Cui CX, Yue YJ, Gao S et al (2022) MRI comparative study of diffuse midline glioma, H3 K27M-altered and glioma in the midline without H3K27-altered. BMC Neurol 22:498. https://doi.org/10.1186/s12883-022-03026-0
doi: 10.1186/s12883-022-03026-0 pubmed: 36550486 pmcid: 9773507
Zheng L, Gong J, Yu T, Zou Y, Zhang M, Nie L et al (2022) Diffuse midline gliomas with histone H3 mutation in adults and children. Am J Surg Pathol 46:863–871. https://doi.org/10.1097/PAS.0000000000001897
doi: 10.1097/PAS.0000000000001897 pubmed: 35416795 pmcid: 9093723

Auteurs

Nobuhide Hayashi (N)

Department of Neurosurgery, Wakayama Rosai Hospital, Kinomoto 93-1, Wakayama City, Wakayama, 640-8505, Japan. nbh-hayashi@wakayamah.johas.go.jp.
Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan. nbh-hayashi@wakayamah.johas.go.jp.
Department of Neurological Surgery, School of Medicine, Wakayama Medical University, Kimiidera 811-1, Wakayama City, Wakayama, 641-8510, Japan. nbh-hayashi@wakayamah.johas.go.jp.
ORCID: 0009-0003-3137-7927

Junya Fukai (J)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan. junfukai@wakayama-med.ac.jp.
Department of Neurological Surgery, School of Medicine, Wakayama Medical University, Kimiidera 811-1, Wakayama City, Wakayama, 641-8510, Japan. junfukai@wakayama-med.ac.jp.

Hirokazu Nakatogawa (H)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Pediatric Neurosurgery, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, 430-8558, Japan.
Department of Neurosurgery, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, 430-8558, Japan.

Hiroshi Kawaji (H)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, 430-8558, Japan.

Ema Yoshioka (E)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Division of Molecular Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.

Yoshinori Kodama (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka City, Osaka, 541-8567, Japan.

Kosuke Nakajo (K)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka Metropolitan University Graduate School of Medicine, Osaka City, Osaka, 545-8585, Japan.

Takehiro Uda (T)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka Metropolitan University Graduate School of Medicine, Osaka City, Osaka, 545-8585, Japan.

Kentaro Naito (K)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka Metropolitan University Graduate School of Medicine, Osaka City, Osaka, 545-8585, Japan.

Noriyuki Kijima (N)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.

Yoshiko Okita (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.

Naoki Kagawa (N)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan.

Yoshinobu Takahashi (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, School of Medical Science, Kyoto Prefectural University Graduate, Kyoto City, Kyoto, 602-8566, Japan.

Naoya Hashimoto (N)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, School of Medical Science, Kyoto Prefectural University Graduate, Kyoto City, Kyoto, 602-8566, Japan.

Hideyuki Arita (H)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka International Cancer Institute, Osaka City, Osaka, 541-8567, Japan.

Koji Takano (K)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka International Cancer Institute, Osaka City, Osaka, 541-8567, Japan.

Daisuke Sakamoto (D)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Hyogo, 663-8501, Japan.

Tomoko Iida (T)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Hyogo, 663-8501, Japan.

Yoshiki Arakawa (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto City, Kyoto, 606-8507, Japan.

Takeshi Kawauchi (T)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka Red Cross Hospital, Osaka City, Osaka, 543-8555, Japan.

Yukihiko Sonoda (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Faculty of Medicine, Yamagata University, Yamagata City, Yamagata, 990-8560, Japan.

Yuta Mitobe (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Faculty of Medicine, Yamagata University, Yamagata City, Yamagata, 990-8560, Japan.

Kenichi Ishibashi (K)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka City General Hospital, Osaka City, Osaka, 534-0021, Japan.

Masahide Matsuda (M)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305-8575, Japan.

Takamune Achiha (T)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Kansai Rosai Hospital, Amagasaki, Hyogo, 660-8511, Japan.

Takahiro Tomita (T)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama City, Toyama, 930-0194, Japan.

Masahiro Nonaka (M)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Kansai Medical University, Hirakata, Osaka, 573-1191, Japan.

Keijiro Hara (K)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima City, Tokushima, 770-8501, Japan.

Noriyoshi Takebe (N)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Medical Research Institute, Tazuke Kofukai Foundation, Kitano Hospital, Osaka City, Osaka, 530-8480, Japan.

Takashi Tsuzuki (T)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Sakai City Medical Center, Sakai, Osaka, 593-8304, Japan.

Yoshikazu Nakajima (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Sakai City Medical Center, Sakai, Osaka, 593-8304, Japan.
Department of Neurosurgery, Kobe Tokushukai Hospital, Kobe, Hyogo, 655-0017, Japan.

Shiro Ohue (S)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Ehime Prefectural Central Hospital, Matsuyama, Ehime, 790-0024, Japan.

Nobuyuki Nakajima (N)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Tokyo Medical University, Tokyo, 160-0023, Japan.

Akira Watanabe (A)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Kindai University Nara Hospital, Ikoma, Nara, 630-0293, Japan.

Akihiro Inoue (A)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Ehime University School of Medicine, Toon, Ehime, 791-0295, Japan.

Masao Umegaki (M)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Suita Municipal Hospital, Suita, Osaka, 564-8567, Japan.

Daisuke Kanematsu (D)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Division of Molecular Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.

Asako Katsuma (A)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.

Miho Sumida (M)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.

Tomoko Shofuda (T)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.

Masayuki Mano (M)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Central Laboratory and Surgical Pathology, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.

Manabu Kinoshita (M)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Osaka International Cancer Institute, Osaka City, Osaka, 541-8567, Japan.
Department of Neurosurgery, Asahikawa Medical University, Asahikawa, Hokkaido, 078-8510, Japan.

Kanji Mori (K)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, Yao Municipal Hospital, Yao, Osaka, 581-0069, Japan.

Naoyuki Nakao (N)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Department of Neurological Surgery, School of Medicine, Wakayama Medical University, Kimiidera 811-1, Wakayama City, Wakayama, 641-8510, Japan.

Yonehiro Kanemura (Y)

Kansai Molecular Diagnosis Network for CNS Tumors, Osaka City, Osaka, 540-0006, Japan.
Division of Molecular Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.
Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.
Department of Neurosurgery, NHO Osaka National Hospital, Osaka City, Osaka, 540-0006, Japan.

Classifications MeSH